26 Mar, 2026

African drugmaker Aspen posts $63 million loss due to contract dispute

African drugmaker Aspen posts $63 million loss due to contract dispute

South Africa’s Aspen Pharmacare made a full-year loss after tax of 1.1 billion rand ($63 million), it said on Wednesday, citing the impact of a material contractual manufacturing dispute and asset impairments of 4.1 billion rand.

The loss in the year ended June 30 compared to a profit after tax of 4.4 billion rand the previous year. Group revenue edged 1% higher to 43 billion rand.

The dispute, the details of which are subject to contractual confidentiality, relates to a manufacturing and technology agreement with a contract manufacturing customer for mRNA products, Aspen said.

Manufacturing revenue fell 21% to 11.1 billion rand, while normalized earnings before interest, tax, depreciation and amortization of 668 million rand in constant currency ended 62% lower than the previous year, impacted mainly by the dispute within the finished dose form segment, the company said.

The dispute is the subject of a contractually prescribed adjudication process, Aspen said.

The company declared a gross dividend of 211 cents per share, down 41%.

($1 = 17.5632 rand)

(Reporting by Nqobile Dludla; ​​editing by Barbara Lewis)